IART Integra Lifesciences Holdings Corp

Price (delayed)

$56.46

Market cap

$4.72B

P/E Ratio

27.28

Dividend/share

N/A

EPS

$2.07

Enterprise value

$5.92B

Integra LifeSciences is a global leader in regenerative tissue technologies and neurosurgical solutions dedicated to limiting uncertainty for clinicians, so they can focus on providing the best patient care. Integra ...

Highlights
The stock's price to earnings (P/E) is 51% less than its 5-year quarterly average of 55.9 and 6% less than its last 4 quarters average of 29.0
IART's quick ratio is up by 20% YoY and by 8% from the previous quarter
Integra Lifesciences Holdings's net income has decreased by 20% YoY but it has increased by 4% from the previous quarter
IART's EPS is down by 19% year-on-year but it is up by 4.5% since the previous quarter
The debt is up by 3.7% year-on-year

Key stats

What are the main financial stats of IART
Market
Shares outstanding
83.52M
Market cap
$4.72B
Enterprise value
$5.92B
Valuations
Price to earnings (P/E)
27.28
Price to book (P/B)
2.73
Price to sales (P/S)
3
EV/EBIT
23.64
EV/EBITDA
15.84
EV/Sales
3.78
Earnings
Revenue
$1.57B
EBIT
$250.3M
EBITDA
$373.62M
Free cash flow
$193.1M
Per share
EPS
$2.07
Free cash flow per share
$2.33
Book value per share
$20.65
Revenue per share
$18.85
TBVPS
$21.38
Balance sheet
Total assets
$3.81B
Total liabilities
$2.08B
Debt
$1.71B
Equity
$1.72B
Working capital
$892M
Liquidity
Debt to equity
0.99
Current ratio
3.93
Quick ratio
2.5
Net debt/EBITDA
3.22
Margins
EBITDA margin
23.9%
Gross margin
61.9%
Net margin
11.1%
Operating margin
14.7%
Efficiency
Return on assets
4.6%
Return on equity
10.4%
Return on invested capital
9.8%
Return on capital employed
7.1%
Return on sales
16%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

IART stock price

How has the Integra Lifesciences Holdings stock price performed over time
Intraday
0.18%
1 week
4.56%
1 month
15.55%
1 year
-11.3%
YTD
-15.72%
QTD
33.29%

Financial performance

How have Integra Lifesciences Holdings's revenue and profit performed over time
Revenue
$1.57B
Gross profit
$969.5M
Operating income
$229.3M
Net income
$172.99M
Gross margin
61.9%
Net margin
11.1%
The net margin has declined by 22% year-on-year but it is up by 4.7% since the previous quarter
Integra Lifesciences Holdings's net income has decreased by 20% YoY but it has increased by 4% from the previous quarter
The operating income has grown by 20% year-on-year and by 3.9% since the previous quarter
IART's operating margin is up by 17% year-on-year and by 4.3% since the previous quarter

Growth

What is Integra Lifesciences Holdings's growth rate over time

Valuation

What is Integra Lifesciences Holdings stock price valuation
P/E
27.28
P/B
2.73
P/S
3
EV/EBIT
23.64
EV/EBITDA
15.84
EV/Sales
3.78
The stock's price to earnings (P/E) is 51% less than its 5-year quarterly average of 55.9 and 6% less than its last 4 quarters average of 29.0
IART's EPS is down by 19% year-on-year but it is up by 4.5% since the previous quarter
The P/B is 20% lower than the 5-year quarterly average of 3.4 and 6% lower than the last 4 quarters average of 2.9
The equity has increased by 6% year-on-year and by 3.8% since the previous quarter
The price to sales (P/S) is 9% less than the 5-year quarterly average of 3.3 and 3.2% less than the last 4 quarters average of 3.1
The revenue is up by 2.6% year-on-year

Efficiency

How efficient is Integra Lifesciences Holdings business performance
Integra Lifesciences Holdings's return on equity has decreased by 25% YoY but it has increased by 3% QoQ
IART's ROA is down by 21% YoY but it is up by 4.5% QoQ
IART's return on invested capital is down by 6% year-on-year
IART's return on sales is down by 5% year-on-year but it is up by 3.9% since the previous quarter

Dividends

What is IART's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for IART.

Financial health

How did Integra Lifesciences Holdings financials performed over time
The company's total assets is 83% higher than its total liabilities
IART's quick ratio is up by 20% YoY and by 8% from the previous quarter
The current ratio has grown by 18% year-on-year and by 2.1% since the previous quarter
The equity has increased by 6% year-on-year and by 3.8% since the previous quarter
The debt is up by 3.7% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.